Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous
peripheral blood T-lymphocyte (PD1-T) combined with docetaxel in the second-line treatment of
IIIB/IIIC/IV non-small cell lung cancer. Half of participants receive PD1-T combined with
docetaxel, while the other half will receive docetaxel.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital